Association of Early-Life Cognitive Enrichment With Alzheimer Disease Pathological Changes and Cognitive Decline
- PMID: 32597941
- PMCID: PMC7325069
- DOI: 10.1001/jamaneurol.2020.1941
Association of Early-Life Cognitive Enrichment With Alzheimer Disease Pathological Changes and Cognitive Decline
Abstract
Importance: Indicators of early-life cognitive enrichment (ELCE) have been associated with slower cognitive decline and decreased dementia in late life. However, the mechanisms underlying this association have not been elucidated.
Objective: To examine the association of ELCE with late-life Alzheimer disease (AD) and other common dementia-related pathological changes.
Design, setting, and participants: This clinical-pathological community-based cohort study, the Rush Memory and Aging Project, followed up participants before death for a mean (SD) of 7.0 (3.8) years with annual cognitive and clinical assessments. From January 1, 1997, through June 30, 2019, 2044 participants enrolled, of whom 1018 died. Postmortem data were leveraged from 813 participants. Data were analyzed from April 12, 2019, to February 20, 2020.
Exposures: Four indicators of ELCE (early-life socioeconomic status, availability of cognitive resources at 12 years of age, frequency of participation in cognitively stimulating activities, and early-life foreign language instruction) were obtained by self-report at the study baseline, from which a composite measure of ELCE was derived.
Main outcomes and measures: A continuous global AD pathology score derived from counts of diffuse plaques, neuritic plaques, and neurofibrillary tangles.
Results: The 813 participants included in the analysis had a mean (SD) age of 90.1 (6.3) years at the time of death, and 562 (69%) were women. In a linear regression model controlled for age at death, sex, and educational level, a higher level of ELCE was associated with a lower global AD pathology score (estimate, -0.057; standard error, 0.022; P = .01). However, ELCE was not associated with any other dementia-related pathological changes. In addition, a higher level of ELCE was associated with less cognitive decline (mean [SD], -0.13 [0.19] units per year; range, -1.74 to 0.85). An indirect effect through AD pathological changes constituted 20% of the association between ELCE and the rate of late-life cognitive decline, and 80% was a direct association.
Conclusions and relevance: These findings suggest that ELCE was associated with better late-life cognitive health, in part through an association with fewer AD pathological changes.
Conflict of interest statement
Figures
Comment in
-
Modifiable Lifestyle Factors in Alzheimer Disease: An Opportunity to Transform the Therapeutic Landscape Through Transdisciplinary Collaboration.JAMA Neurol. 2020 Oct 1;77(10):1207-1209. doi: 10.1001/jamaneurol.2020.1114. JAMA Neurol. 2020. PMID: 32597936 No abstract available.
Similar articles
-
Association of Cognitive Function Trajectories in Centenarians With Postmortem Neuropathology, Physical Health, and Other Risk Factors for Cognitive Decline.JAMA Netw Open. 2021 Jan 4;4(1):e2031654. doi: 10.1001/jamanetworkopen.2020.31654. JAMA Netw Open. 2021. PMID: 33449094 Free PMC article.
-
Association of Delirium With Cognitive Decline in Late Life: A Neuropathologic Study of 3 Population-Based Cohort Studies.JAMA Psychiatry. 2017 Mar 1;74(3):244-251. doi: 10.1001/jamapsychiatry.2016.3423. JAMA Psychiatry. 2017. PMID: 28114436 Free PMC article.
-
Association of Cortical β-Amyloid Protein in the Absence of Insoluble Deposits With Alzheimer Disease.JAMA Neurol. 2019 Jul 1;76(7):818-826. doi: 10.1001/jamaneurol.2019.0834. JAMA Neurol. 2019. PMID: 31009033 Free PMC article.
-
Pathophysiological Association of Alzheimer's Disease and Hypertension: A Clinical Concern for Elderly Population.Clin Interv Aging. 2023 May 5;18:713-728. doi: 10.2147/CIA.S400527. eCollection 2023. Clin Interv Aging. 2023. PMID: 37181536 Free PMC article. Review.
-
Insulin resistance, cognition, and Alzheimer disease.Obesity (Silver Spring). 2023 Jun;31(6):1486-1498. doi: 10.1002/oby.23761. Obesity (Silver Spring). 2023. PMID: 37203336 Review.
Cited by
-
Assessing Cannabidiol as a Therapeutic Agent for Preventing and Alleviating Alzheimer's Disease Neurodegeneration.Cells. 2023 Nov 21;12(23):2672. doi: 10.3390/cells12232672. Cells. 2023. PMID: 38067101 Free PMC article.
-
Availability of Cognitive Resources in Early Life Predicts Transitions Between Cognitive States in Middle and Older Adults From Europe.Innov Aging. 2023 Oct 26;7(9):igad124. doi: 10.1093/geroni/igad124. eCollection 2023. Innov Aging. 2023. PMID: 38034934 Free PMC article.
-
Epigenetic age acceleration as a biomarker for impaired cognitive abilities in adulthood following early life adversity and psychiatric disorders.Neurobiol Stress. 2023 Oct 15;27:100577. doi: 10.1016/j.ynstr.2023.100577. eCollection 2023 Nov. Neurobiol Stress. 2023. PMID: 37885906 Free PMC article.
-
Prevalence and modifiable risk factors for dementia in persons with intellectual disabilities.Alzheimers Res Ther. 2023 Jul 18;15(1):125. doi: 10.1186/s13195-023-01270-1. Alzheimers Res Ther. 2023. PMID: 37464412 Free PMC article.
-
Effects of early-life environment and adulthood SES on cognitive change in a multiethnic cohort.J Int Neuropsychol Soc. 2023 Oct;29(8):742-750. doi: 10.1017/S135561772200087X. Epub 2023 Mar 7. J Int Neuropsychol Soc. 2023. PMID: 36880230 Free PMC article.
